Estrella Immunopharma annual total liabilities
2021
2022
2022
2023
2024
2024
2025
Estrella Immunopharma Total Liabilities Growth & History (ESLA)
Estrella Immunopharma's total liabilities was $13.5M for fiscal 2025.
View full Estrella Immunopharma company overviewEstrella Immunopharma annual total liabilities history
| Fiscal year | Period ended | Total liabilities | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $13.5M | $10.5M | +351.88% |
| 2024 · Dec 31 | 2024-12-31 | $3.0M | — | — |
| 2024 · Jun 30 | 2024-06-30 | $180,701 | −$9.6M | −98.15% |
| 2023 | 2023-06-30 | $9.8M | $3.8M | +63.90% |
| 2022 | 2022-12-31 | $2.7M | $1.0M | +63.40% |
| 2022 | 2022-06-30 | $6.0M | — | — |
| 2021 | 2021-12-31 | $1.6M | — | — |
Estrella Immunopharma quarterly total liabilities
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total liabilities | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $9.3M | $180,819 | +1.99% |
| Q1 2026 | 2026-03-31 | $8.9M | $4.7M | +108.82% |
| Q4 2025 | 2025-12-31 | $13.5M | $10.5M | +351.88% |
| Q3 2025 | 2025-09-30 | $13.4M | $10.4M | +346.99% |
| Q2 2025 | 2025-06-30 | $9.1M | $8.9M | +4922.22% |
| Q1 2025 · Mar 31 | 2025-03-31 | $4.3M | $4.1M | +2987.00% |
| Q4 2024 · Dec 31 | 2024-12-31 | $3.0M | $2.6M | +651.64% |
| Q1 2025 · Sep 30 | 2024-09-30 | $3.0M | −$14.3M | −82.70% |
| Q4 2024 · Jun 30 | 2024-06-30 | $180,701 | −$9.6M | −98.15% |
| Q3 2024 | 2024-03-31 | $138,491 | — | — |
| Q2 2024 | 2023-12-31 | $398,733 | −$2.3M | −84.97% |
| Q1 2024 | 2023-09-30 | $17.3M | $15.0M | +655.85% |
| Q4 2023 | 2023-06-30 | $9.8M | $8.1M | +473.03% |
| Q4 2022 | 2022-12-31 | $2.7M | $1.0M | +63.40% |
| Q3 2022 | 2022-09-30 | $2.3M | $635,154 | +38.47% |
| Q2 2022 | 2022-06-30 | $1.7M | — | — |
| Q1 2022 | 2022-03-31 | $1.6M | — | — |
| Q4 2021 | 2021-12-31 | $1.6M | — | — |
| Q3 2021 | 2021-09-30 | $1.7M | — | — |
Estrella Immunopharma total liabilities trends
Between the periods ended 2021-12-31 and 2025-12-31, Estrella Immunopharma's total liabilities increased from $1.6M to $13.5M, a change of $11.9M. The latest reported quarter, Q2 2026, shows $9.3M.
About the metric
What total liabilities mean
Total liabilities are all obligations reported on a company’s balance sheet, including debt, accounts payable, accrued expenses, deferred revenue, lease liabilities, and other current and long-term obligations.
Calculation and source
SEC-reported and calculated total liabilities
TickerStat uses total liabilities reported in company SEC filings when available. Otherwise, it calculates total liabilities as aligned total assets minus total equity for the same balance-sheet date. Total liabilities should not be confused with interest-bearing debt. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Estrella Immunopharma source filings ↗